Selvita releases the results of SEL24 oncology program

Kraków, Poland – November 12, 2009 – Selvita Ltd.has released the results of its SEL24 oncology program. The most recent data was presented during a poster session of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2009. Selvita presented the poster # A242, titled “Identification of novel and specific Pim-1 kinase inhibitors with potent anticancer activity in hematological and solid tumor malignancies”, which reports on the results of a lead optimization study of a new small molecule Pim-1 kinase inhibitor -  SEL24-1. Dr. Nicolas Beuzen, Selvita’s CSO commented about the most recent results: “In order to improve the potency and selectivity of the original compound, a series of new derivatives was synthesized and screened for Pim-1 inhibition. Among the newly synthesized compounds several exerted increased potency in Pim-1 inhibition with IC50 values below 5 nM.  We are very enthusiastic about this progress as results of the optimization efforts clearly support further development of this class of inhibitors in oncology indications.” Pim kinases are one of the most interesting new therapeutic targets which are being currently researched by the biggest pharmaceutical companies in the world. According to the most recent literature reviews  Pim kinases are strongly related to the process of oncogenesis and development of leukemias, prostate cancer, breast cancer, pancreatic cancer, renal cancer and glioblastomas. SEL24 is the major oncology program that Selvita currently has in its pipeline, first-in-human application for SEL24 is planned for 2011. About Selvita Selvita delivers comprehensive solutions to customers from the pharmaceutical and biotechnology industry targeted at lowering the cost of introducing innovative compounds to the market. The areas of our activity include: advanced protein modeling services and software; computer aided drug design; optimization of lead compounds; contract synthesis; information technology for research projects. Selvita also conducts its own innovative research projects for the pharmaceuticals customers, in collaboration with various leading research institutions. Currently projects being developed are in the area of oncology and central nervous system. For more information about the project or the company, please contact: This e-mail address is being protected from spam bots, you need JavaScript enabled to view it   Selvita to Present a Poster on the Developments of Its Oncology Program During the 2009 AACR-NCI-EORTC International Conference